Shellie Fravel, PharmD

Agree!

Yes so…

-Lovaza 3 capsules 1395 EPA / 1125 DHA
-Lovaza 4 capsules 1860 EPA / 1500 DHA

vs

-Study 4 capsules 1600 EPA / 800 DHA

I guess the question is if either regimen is close enough to presume equal benefit/safety?

Have you tried prescribing generic Lovaza? I think that it’s a close match to the EPA/DHA content in the trial if you order 2 capsules BID.

I think Lovaza is close. Each 1g capsule contains 465 mg EPA and 375 mg DHA and is dosed as 4 capsules a day for high TG. It is also available generic now so reasonably priced. #NephJC www.costplusdrugs.com/medications/...

Shellie Fravel joining from Iowa City. No COI. #NephJC

Fish Oil in Dialysis: A Big Catch or an Empty Net — NephJC Holy Mackerel! This week we will discuss fish oil use in maintenance hemodialysis patients. Could this be the one thing that bends the curve on CV mortality, or is it just a red herring?

Maybe the most shocking study from #KidneyWk.
🐚From the depths of the oceans to #BlueSky, we're discussing PISCES 🐟 12/2/25 9pm EST. #NephJC
Are you hooked🪝on fish oil for CV disease in ESRD, or are you throwing it back 🌊?
www.nephjc.com/news/pisces-fishoil

PISCES: The Visual Abstract — NephJC Curious how n-3 PUFAs may cut serious cardiovascular events in dialysis? 🐟 A big signal, a big dose, and a big discussion ahead — don’t miss this #NephJC! Check out the VA made by our master Brian...

Holy Mackerel! 🐟
🦜Ahoy matey! Could fish oil unlock the mysteries of increased CV mortality in ESRD? 🏴‍☠️ #NephJC
Join us for a lively trawling trip 12/2/25 🛥️at 9pm EST
Check out the PISCES VA by @brianrifkin.bsky.social
www.nephjc.com/news/piscesva

Should be 1-2 pm on Dec 3 for you in AUS…if I’ve done my time conversion correctly!

1/10
Last #NephJC we discussed the ORIGIN 3 trial which investigated the use of Atacicept in IgAN #TenPostNephJC
Read the article 👇
www.nejm.org/doi/10....

Hope you can join Kevan! @dialysisbloke.bsky.social

A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy | NEJM IgA nephropathy, the most common primary glomerulopathy worldwide, is a kidney disorder of B-cell origin characterized by mesangial accumulation of IgA-containing immune complexes. In at least 50% ...

In just 30 min we will start #NephJC chat on our @nejm.org trial tonight, we’ll explore IgAN treatment closer to pathophysiology ORIGIN with a simultaneous publication during #KidneyWk

Attacking the Origin of IgAN: ORIGIN3 and Atacicept — NephJC This week, we will discuss the phase 3 ORIGIN3 trial of atacicept, an APRIL/BAFF inhibitor for use in IgAN.

Tonite 11/18/25 on #Bluesky 9pm EST
We are discussing ORIGIN3 and atacicept in IgAN.
APRIL, BAFF and B-cells, Oh My! (🦁🐯🐻)
It's going to be Wicked good. 🧙‍♀️ #NephJC
Summary by @notjustdialysis.bsky.social
www.nephjc.com/news/atacicept-origin3-gtfb36

High measured GFR as a predictor of all-cause mortality and cardiovascular disease in a prospective non-diabetic population cohort ABSTRACTBackground. High glomerular filtration rate (GFR) is generally regarded as beneficial but has been associated with cardiovascular disease (CVD) and

High measured GFR as a predictor of all-cause mortality and cardiovascular disease in a prospective non-diabetic population cohort
More info:https://academic.oup.com/ndt/article/40/11/2091/8122110
@ndt-era.bsky.social, @hjanders.bsky.social

Kidney Week in Houston: Day 2 — NephJC in this edition: Fish Oil, GBD, Flozination meta-analysis, CHW intervention in Hispanic/Latino patients, and much more

Missing all the overwhelming amount of science coming out of #KidneyWk?

The #NephJC crew has got you covered

Day 2 edition www.nephjc.com/news/kidneyw... via @nephroseeker.medsky.social & moi

Indications for mineralocorticoid receptor antagonists (MRAs) in the management of cardio-kidney risk
#KidneyWk #Nephpearls #NephSky #Cardiorenal

✅ Check out this resource from @theisn.org
@isnkidneycare.bsky.social

👉 www.theisn.org/initiatives/...

Very proud to have lead the Australian arm of PISCES. Huge thanks for Charmaine Lok for the collaboration.

Kidney Week in Houston: Day 1 — NephJC in this edition: Atacicept in IgAN; Albuminuria as a surrogate outcome, Renal Remission and additional CONFIDENCE analysis

Got #KidneyWk FOMO like @nephroseeker.medsky.social ?

We got you covered with daily coverage of the simultaneous publications!

www.nephjc.com/news/kidneyw...

Shellie Fravel, PharmD joining from Iowa City. No COI. Ready to learn lots tonight! #NephJC

2025 IgAN KDIGO guidelines: fresh out of press, already aging gracefully — NephJC This week, we will discuss the 2025 KDIGO IgAN guidelines. which the shift from supportive care to structured, evidence-based therapy

The 2025 @kdigo.org IgAN guideline quietly redraws the map: new drugs, new thresholds, and a sense that the era of “supportive care only” is finally over #Nephsky #Medsky

✍️Summary by @thekidneywhisperer.bsky.social and
@glomerican.bsky.social

www.nephjc.com/news/igan-kd...

KDIGO 2025 IgA guidelines - Visual Abstract — NephJC KDIGO 2025 is here. IgAN management is evolving with precision risk tools, new therapies, and a stronger focus on kidney protection. Check out the visual abstract created by Natalia Nombera

⏩ Next #NephJC is on IgA nephropathy @kdigo.org guideline

🎨 Nice visual summary by @roxnonna23.bsky.social

www.nephjc.com/news/2025/10...

Empagliflozin, the kidney, and what we still don’t understand — NephJC NephJC short on an empagliflozin meta-analysis

Last #NephJC short on individual data meta-analysis showing that although we love flozins for their extensive benefits we actually don’t completely understand how they work #Nephsky

✍️Meta by @willkidney.bsky.social & co
📝 Write up by @nephroseeker.medsky.social

www.nephjc.com/news/2025/10...

Moving forward from Cockcroft-Gault creatinine clearance to race-free estimated glomerular filtration rate to improve medication-related decision-making in adults across healthcare settings: A consens... The NKF Workgroup for Implementation of Race-Free eGFR-Based Medication-Related Decisions suggests that health systems, health settings, clinical laboratories, electronic health record systems, compen...

Yes! It needs to go! We should be using BSA adjusted, race-free eGFR. pubmed.ncbi.nlm.nih.gov/39552516/

A Review of the Management of Nephrolithiasis in Autosomal Dominant Polycystic Kidney Disease Autosomal dominant polycystic kidney disease (ADPKD) is a chronic hereditary disorder and a major cause of end-stage renal disease (ESRD). Urolithiasis is a frequent complication in ADPKD and may cont...

A Review of the Management of Nephrolithiasis in Autosomal Dominant Polycystic Kidney Disease - goo.gl/alerts/LioZE5 #GoogleAlerts

Journal Club: low protein diet Effect of a very low protein diet on outcome: long-term follow-up.This is the long-term follow-up of the B group from the original MDRD study.Enrollment criteria:Age: 18-70Abnormal Cr 1.2-7 women 1…

Here’s @kidneyboy.bsky.social take on that study

pbfluids.com/2009/02/jour...

#NephJC

Shellie Fravel, PharmD joining from Iowa City. No COI…not a big fan of restricting or supplementing. Looking forward to a good discussion tonight! #NephJC

🫘 In advanced #CKD, protein supplementation boosts 📈 serum albumin (+1.76 g/L) & BMI (+0.29 kg/m²) but ❌ does not significantly improve health-related quality of life (HRQOL).

🔎 17 RCTs | 5699 screened
⚠️ Bias, short duration, heterogeneity

#NephJC

Suplementación con proteínas en la ERC: El Resumen Visual — NephJC ¿La suplementación con proteínas mejora la calidad de vida en la ERC avanzada? Revisa este resumen visual creado por Marc Soco , que sintetiza una nueva revisión sistemática y metanálisis! ¡No olvi...

Check out the Spanish VA. #NephSky
Como siempre muchas gracias @dramiliflores.bsky.social

www.nephjc.com/news/2025/10/12/suplementacion-con-protenas-en-la-erc-el-resumen-visual

Protein supplementation in CKD: The Visual Abstract — NephJC We like protein, or do we? Low protein, high protein, supplements…what’s a nephrologist to do?

Check at the VA for our discussion of protein diet strategies by @msocomd.bsky.social. Is restricting protein in CKD and pushing protein in ESRD #TWDFNR?

www.nephjc.com/news/2025/10...

The Protein Pendulum in CKD: supplement or restrict? — NephJC This week, we will discuss an old dilemma in nephrology. To restrict or supplement the proteins? Premise: advanced CKD and dialysis.

🗓️Join us 10/14/25 as we discuss:
Are you team PRO protein 💪 or team RESTRICT protein 🥗
The strategies seem to shift somewhat as CKD progresses to ESRD. What's the evidence say 🤔?
🕰️9pm EST only on Bluesky. #NephSky #MedSky
www.nephjc.com/news/proteins-eskd

T2g
In fact, many GNs have a high risk of recurrence and were excluded from this study.
Since the recurrence of IgAN was not unexpected, should those patients have been excluded from this protocol? #NephJC